Current Status Towards 90-90-90 UNAIDS Target and Factors Associated with HIV Viral Load Suppression in Kediri City, Indonesia

References

• UNAIDS. UNAIDS 2016–2021 Strategy: on the Fast-Track to End AIDS. Geneva, Switzerland: UNAIDS; 2016 Available from: unaids.org. Accessed 17, 2020.
   Google Scholar
• UNAIDS. Fast-Track: Ending the AIDS Epidermic by 2030. Geneva, Switzerland: UNAIDS; 2014.
   Google Scholar
• UNAIDS. HIV Prevention 2020 Road Map. Geneva, Switzerland: UNAIDS; 2016 Available from: unaids.org. Accessed 17, 2020.
   Google Scholar
• World Health Organisation. World Health Organization. Progress Report on Prevent HIV, Test and Treat All. Geneva, Switzerland: World Health Organisation; 2016.
   Google Scholar
• Das M, Chu PL, Santos G, Scheer S, Vittinghoff ECG. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One. 2010;5:6. doi:10.1371/journal.pone.0011068
   Google Scholar
• UNAIDS. Understanding Fast Track; Accelerating Action to End the AIDS Epidemic by 2030. Geneva, Switzerland: UNAIDS; 2015 Available from: unaids.org. Accessed 17, 2020.
   Google Scholar
• Croxford S, Kitching A, Desai S; GBD 2015 Eastern Mediterranean Region HIV/AIDS Collaborators. Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort. Lancet Public Health. 2017;2(1):e35–e46. doi:10.1016/S2468-2667(16)30020-229249478
   PubMed Web of Science ®Google Scholar
• UNAIDS. Ending AIDS Progress Towards the 90- 90-90targets. Geneva, Switzerland: UNAIDS; 2017 UNAIDS/JC2900E.
   Google Scholar
• UNAIDS. The Need for Routine Viral Load Testing. Geneva, Switzerland: UNAIDS; 2016.
   Google Scholar
• UNAIDS. HIV PREVENTION GAP REPORT. Geneva, Switzerland: UNAIDS; 2016 Available from: unaids.org. Accessed 17, 2020.
   Google Scholar
• UNAIDS. Fact Sheet - 2018 GLOBAL HIV STATISTICS 2019. Geneva, Switzerland: UNAIDS; 2019.
   Google Scholar
• Kementerian Kesehatan Republik Indonesia. InfoDatin: Situasi Umum HIV/AIDS Dan Tes HIV. Jakarta: Kementerian Kesehatan Republik Indonesia; 2018. Indonesian. 
   Google Scholar
• UNAIDS. Tuberculosis and HIV- Progress Towards the 2020 Target. Geneva, Switzerland: UNAIDS; 2019 Available from: http://www.unaids.org/sites/default/files/media_asset/tuberculosis-and-hiv-progress-towards-the-2020-target_en.pdf. Accessed 17, 2020.
   Google Scholar
• UNAIDS. Global HIV Statistics 2018. Geneva, Switzerland: UNAIDS: 2019.
   Google Scholar
• Kementerian Kesehatan RI Indonesia health profile, 2017. 2018 Available from: http://www.kemkes.go.id. Accessed January 7, 2020. Indonesian.
   Google Scholar
• Globerman J, Gogolishvili DRS. Evidence Review: HIV Sexual Transmission Risk by People with Suppressed HIV Viral Load. Ontario HIV Treatment Network  Toronto; 2017.
   Google Scholar
• Del Romero J, Castilla J, Hernando V, Rodríguez CGS. Combined antiretroviral treatment and heterosexual transmission of HIV-1: cross sectional and prospective cohort study. BMJ. 2010;340(7757):1179. doi:10.1136/bmj.c2205
   Google Scholar
• Centers for Disease Control and Prevention. CDC Fact Sheet: Today’s HIV/AIDS Epidemic. United States: Centers for Disease Control and Prevention; 2016.
   Google Scholar
• Kementerian Kesehatan Republik Indonesia. Laporan Kineja Kementrian Kesehatan Tahun 2015. Jakarta: Kementerian Kesehatan Republik Indonesia; 2015. Indonesian.
   Google Scholar
• Januraga PP, Reekie J, Mulyani T, et al. The cascade of HIV care among key populations in Indonesia: a prospective cohort study. Lancet HIV. 2018;5(10):e560–e568. doi:10.1016/S2352-3018(18)30148-630143455
   PubMed Web of Science ®Google Scholar
• Granich R, Gupta S, Wollmers M, Ruffner MWB. Modeling the HIV epidemic: why the 95- 95-95Target and ART effectiveness parameters matter. Int J Virol AIDS. 2018;5:1. doi:10.23937/2469-567x/1510041
   Google Scholar
• Centers for Disease Control and Prevention. Evidence of HIV Treatment and Viral Suppression in Preventing the Sexual Transmission of HIV. United States: Centers for Disease Control and Prevention; 2018 Available from: https://www.cdc.gov/hiv/pdf/risk/art/cdc-hiv-art-viral-suppression.pdf. Accessed January 14, 2020.
   Google Scholar
• Arkell CHM. HIV Treatment and an Undetectable Viral Load to Prevent HIV Transmission FACT. Canadian AIDS Treatment Information Exchnage (CATIE) Toronto; 2018.
   Google Scholar
• Bvochora T, Satyanarayana S, Takarinda KC, et al. Enhanced adherence counselling and viral load suppression in HIV seropositive patients with an initial high viral load in Harare, Zimbabwe: operational issues. PLoS One. 2019;14(2):1–13. doi:10.1371/journal.pone.0211326
   Google Scholar
• World Health Organisation. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. Geneva, Switzerland: World Health Organization; 2013.
   Google Scholar
• World Health Organisation. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection; Recommendations for a Public Health Approach. 2nd Geneva, Switzerland: World Health Organization; 2016.
   Google Scholar
• Etoori D, Ciglenecki I, Ndlangamandla M, et al. Successes and challenges in optimizing the viral load cascade to improve antiretroviral therapy adherence and rationalize second-line switches in Swaziland. J Int AIDS Soc. 2018;21(10):1–8. doi:10.1002/jia2.25194
   Google Scholar
• Rangarajan S, Colby DJ, Le Truong G, et al. Factors associated with HIV viral load suppression on antiretroviral therapy in Vietnam. J Virus Erad. 2016;2:94–101.27482442
   PubMedGoogle Scholar
• Huerga H, Van Cutsem G, Farhat JB, et al. Progress towards the UNAIDS 90- 90-90goals by age and gender in a rural area of KwaZulu-Natal, South Africa: a household-based community cross-sectional survey. BMC Public Health. 2018;18(1):4–11. doi:10.1186/s12889-018-5208-0
   Google Scholar
• Saravanan S, Laeyendecker O, Balakrishnan P, et al. Community viral load, antiretroviral therapy coverage, and HIV incidence in India: a cross-sectional, comparative evaluation study. HHS Public Access. 2016;3(4):1–18. doi:10.1016/S2352-3018(16)00019-9.
   Google Scholar
• Public Health Agency of Canada. Summary: Measuring Canada’s Progress on the 90- 90-90HIV Targets. Canada; 2016 Available from: https://www.canada.ca/content/dam/phac-aspc/documents/services/publications/diseases-conditions/summary-measuring-canada-progress-90-90-90-hiv-targets/hiv90-eng.pdf%0Ahttps://www.canada.ca/content/dam/phac-aspc/documents/services/publications/diseases-con. Accessed January 7, 2020.
   Google Scholar
• O’Connor J, Smith C, Lampe FC, et al. Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study. Lancet HIV. 2017;4(7):e295–e302. doi:10.1016/S2352-3018(17)30053-X28479492
   PubMed Web of Science ®Google Scholar
• Lemeshow S, Hosmer DW, Klar JLS. Adequacy of Sample Size in Health Studies. Vol. 47 NY, USA: John Wiley & Sons Ltd; 1991. doi:10.2307/2532527
   Google Scholar
• UNAIDS. Global AIDS Monitoring 2019: Indicators for Monitoring the 2016 Political Declaration on Ending AIDS. Geneva, Switzerland: UNAIDS; 2019.
   Google Scholar
• UNAIDS. Global AIDS Monitoring 2018: Indicators for Monitoring the 2016 United Nations Political Declaration on Ending AIDS. Geneva, Switzerland: UNAIDS; 2018 Available from: http://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf. Accessed 17, 2020.
   Google Scholar
• Kementerian Kesehatan Republic of Indonesia. Infodatin - situasi penyakit HIV AIDS di Indonesia: pusat data dan informasi Kementerian Kesehatan Republik Indonesia.Jakarta: Kementerian Kesehatan Republik Indonesia; 2016;c:2–6. Indonesian.
   Google Scholar
• World Health Organisation. Guideline on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV: Potential Limitations of Earlier Initiation of Therapy. Geneva, Switzerland; 2015 Available from: http://www.ncbi.nlm.nih.gov/books/NBK327118/. Accessed 17, 2020.
   Google Scholar
• Awungafa G, Amin ET, Fualefac A, et al. Viral load testing and the use of test results for clinical decision making for HIV treatment in Cameroon: an insight into the clinic-laboratory interface. PLoS One. 2018;13(6):3–7. doi:10.1371/journal.pone.0198686
   Google Scholar
• Bain LE, Nkoke CNJ. UNAIDS 90–90–90 targets to end the AIDS epidemic by 2020 are not realistic: comment on “Can the UNAIDS 90–90–90 target be achieved? A systematic analysis of national HIV treatment cascades”. BMJ Glob Health. 2017;2(2):2016–2018. doi:10.1136/bmjgh-2016-000227
   Google Scholar
• Ministry of Health Republic of Indonesia. HIV Epidemiology Review, Indonesia 2016. Jakarta: Kementerian Kesehatan Republik Indonesia; 2017.
   Google Scholar
• Paudel T, Singh N, Banjara MR, Kafle SP, Ghimire YCPB. Epidemiology of HIV, programmatic progress and gaps in last 10 years in Nepal. J Virus Erad. 2016;2(Supplement 4):35–40.28275449
   PubMedGoogle Scholar
• Hoenigl M, Chaillon A, Moore D, et al. Rapid HIV viral load suppression in those initiating antiretroviral therapy at first visit after HIV diagnosis. Sci Rep. 2016;6:1–5. doi:10.1038/srep3294728442746
   PubMedGoogle Scholar
• World Health Organisation. Guideline on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV. Geneva, Switzerland: World Health Organization; 2015.
   Google Scholar
• Batavia AS, Secours R, Espinosa P, Juste MAJ, Severe P, Pape JWFD. Diagnosis of HIV-associated oral lesions in relation to early versus delayed antiretroviral therapy: results from the CIPRA HT001 trial. PLoS One. 2016;11(3):1–7. doi:10.1371/journal.pone.0150656
   Google Scholar
• Sellers CJ, Wohl DA. Antiretroviral therapy: when to start. Infect Dis Clin North Am. 2014;28(3):403–420. doi:10.1016/j.idc.2014.05.00425151563
   PubMedGoogle Scholar
• Hoenigl M, Chaillon A, Little SJ. CD4/CD8 cell ratio in acute HIV infection and the impact of early antiretroviral therapy. Clin Infect Dis. 2016;63(3):425–426. doi:10.1093/cid/ciw29327143670
   PubMedGoogle Scholar
• Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375(9731):2092–2098. doi:10.1016/S0140-6736(10)60705-2.20537376
   PubMed Web of Science ®Google Scholar
• Mbengue M, Chasela C, Onoya D, Mboup S, Fox MED. Clinical predictor score to identify patients at risk of poor viral load suppression at six months on antiretroviral therapy: results from a prospective cohort study in Johannesburg, South Africa. Clin Epidemiol. 2019;11:359–373. doi:10.2147/CLEP.S19774131191029
   PubMed Web of Science ®Google Scholar
• Li X, Ding H, Geng W, et al. Predictive effects of body mass index on immune reconstitution among HIV-infected HAART users in China. BMC Infect Dis. 2019;19(1):1–9. doi:10.1186/s12879-019-3991-630606108
   PubMed Web of Science ®Google Scholar
• Mwamburi DM, Wilson IB, Jacobson DL, et al. Understanding the role of HIV load in determining weight change in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005;40(1):167–173. doi:10.1086/42659115614708
   PubMedGoogle Scholar
• Blashill AJ, Mayer KH, Crane HN, Grasso CSS. Body mass index, immune status and virological control in HIV-infected men who have sex with men. J Natl Inst Health. 2013;12(5):319–324. doi:10.1177/2325957413488182.Body
   Google Scholar